Trade Apellis Pharmaceuticals, Inc. - APLS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.13 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 17.48 |
| Open | 17.1 |
| 1-Year Change | -61.96% |
| Day's Range | 16.94 - 17.5 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 25, 2025 | 17.43 | 0.18 | 1.04% | 17.25 | 17.53 | 16.90 |
| Apr 24, 2025 | 17.48 | 0.03 | 0.17% | 17.45 | 17.87 | 17.23 |
| Apr 23, 2025 | 17.43 | -0.41 | -2.30% | 17.84 | 18.29 | 17.40 |
| Apr 22, 2025 | 17.31 | -0.45 | -2.53% | 17.76 | 18.10 | 16.95 |
| Apr 21, 2025 | 17.96 | 0.01 | 0.06% | 17.95 | 18.65 | 17.61 |
| Apr 17, 2025 | 18.13 | 0.13 | 0.72% | 18.00 | 18.44 | 17.98 |
| Apr 16, 2025 | 18.11 | -0.55 | -2.95% | 18.66 | 18.70 | 17.94 |
| Apr 15, 2025 | 18.89 | -0.12 | -0.63% | 19.01 | 19.61 | 18.66 |
| Apr 14, 2025 | 19.26 | -0.08 | -0.41% | 19.34 | 19.46 | 18.55 |
| Apr 11, 2025 | 19.34 | 0.76 | 4.09% | 18.58 | 19.39 | 18.28 |
| Apr 10, 2025 | 18.72 | 0.01 | 0.05% | 18.71 | 19.17 | 17.40 |
| Apr 9, 2025 | 19.52 | 1.07 | 5.80% | 18.45 | 20.10 | 17.66 |
| Apr 8, 2025 | 18.63 | -1.39 | -6.94% | 20.02 | 20.18 | 18.31 |
| Apr 7, 2025 | 19.75 | 0.80 | 4.22% | 18.95 | 19.82 | 18.11 |
| Apr 4, 2025 | 19.90 | -2.40 | -10.76% | 22.30 | 22.92 | 19.69 |
| Apr 3, 2025 | 22.44 | 0.42 | 1.91% | 22.02 | 23.17 | 21.95 |
| Apr 2, 2025 | 22.92 | 0.56 | 2.50% | 22.36 | 23.03 | 21.86 |
| Apr 1, 2025 | 22.59 | 0.75 | 3.43% | 21.84 | 23.69 | 21.79 |
| Mar 31, 2025 | 21.81 | -1.71 | -7.27% | 23.52 | 23.91 | 21.64 |
| Mar 28, 2025 | 24.22 | 0.21 | 0.87% | 24.01 | 24.30 | 23.56 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company also develops APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration, as well as is in Phase I/II clinical trial for acute respiratory distress syndrome. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam''s base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.| Industry: | Biopharmaceuticals |
100 Fifth Avenue
WALTHAM
MASSACHUSETTS 02451
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com